Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1570-1577

  Bidlingmaier, Scott ^a   He, Jiang ^b   Wang, Yong ^a   An, Feng ^a   Feng, Jinjin ^b   Barbone, Dario ^c   Gao, Dongwei ^b   Franc, Ben ^b   Broaddus, V Courtney F ^c,d   Liu, Bin ^a,d  

^a Department of Anesthesia ^*  (United States)

^b Center for Molecular and Functional Imaging   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; MONOCLONAL ANTIBODY; PROTEOME;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; GENE IDENTIFICATION; IMMUNOTHERAPY; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD146; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOMEGALOVIRUS; EPITOPES; GENE LIBRARY; HUMANS; MAMMALS; MESOTHELIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 60549110525     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1363     Document Type: Article

References (41)

1. Bertazzi PA. Descriptive epidemiology of malignant mesothelioma. Med Lav 2005;96:287-303.
2. Dunleavey R. Malignant mesothelioma: risk factors and current management. Nurs Times 2004;100:40-3.
3. Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004;14:447-60.
4. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-443.
5. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003;42:270-9.
6. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997;4:215-22.
7. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004;45 Suppl 1:S103-19.
8. Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45 Suppl 1:S125-7.
9. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-18.
10. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001;8:555-65.
11. King GD, Curtin JF, Candolfi M, et al. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2005;5:535-57.
12. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A 2005;102:17757-62.
13. Garnett M. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 2001;53:171-216.
14. Zeng L, Fleury-Feith J, Monnet I, et al. Immunocy-tochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol 1994;25:227-34.
15. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
16. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-14.
17. Roth A, Drummond DC, Conrad F, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007;6:2737-46.
18. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631-8.
19. An F, Drummond DC, Wilson S, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008;7:569-78.
20. Bidlingmaier S, Liu B. Construction and application of a yeast surface-displayed human cDNA library to identify posttranslational modification-dependent protein-protein interactions. Mol Cell Proteomics 2006;5:533-40.
21. Bidlingmaier S, Liu B. Interrogating yeast surface-displayed human proteome to identify small molecule-binding proteins. Mol Cell Proteomics 2007;6:2012-20.
22. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986;55:244-8.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
24. Kim KU, Wilson SM, Abayasiriwardana KS, et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005;33:541-8.
25. Schier R, Marks JD, Wolf EJ, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73-81.
26. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 2004;64:704-10.
27. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 2000;301:1149-61.
28. Waibel R, Alberto R, Willuda J, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17:897-901.
29. Sers C, Riethmuller G, Johnson JP. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. Cancer Res 1994;54:5689-94.
30. Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003;102:184-91.
31. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1989;86:9891-5.
32. Sers C, Kirsch K, Rothbacher U, Riethmuller G, Johnson JP. Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci U S A 1993;90:8514-8.
33. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992;167:187-91.
34. Kraus A, Masat L, Johnson JP. Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen. Melanoma Res 1997;7 Suppl 2:S75-81.
35. Shih IM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994;145:837-45.
36. Pacifico MD, Grover R, Richman PI, et al. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005;115:367-75.
37. Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 1998;11:1098-106.
38. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002;62:5106-14.
39. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997;15:553-7.
40. Feldhaus MJ, Siegel RW, Opresko LK, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003;21:163-70.
41. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 2000;18:754-9.